company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12409576.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12409576.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,364533.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1324512.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-895534.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-11616065.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-11616065.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-60639.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-60639.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-60639.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,59965059.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,239807.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,60204866.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,60204866.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,48528162.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16893674.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16893674.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,343763.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1125460.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,8049382.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-7375069.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-7375069.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-330737.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-330737.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-330737.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1121066.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,1121066.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,1121066.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q4,2010-10-01,2010-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-6584740.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9635717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9635717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,326181.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,930414.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-2712944.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-11092066.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-11092066.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-203023.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-203023.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-203023.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1868540.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,1868540.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,1868540.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-9426549.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,3116287.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3116287.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,286750.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1227900.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-891999.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,3738938.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,3738938.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-29539.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-29539.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-29539.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1578007.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,1578007.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,1578007.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,5287406.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,5165193.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5165193.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,238682.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1757023.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-20604354.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13443456.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13443456.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-38959.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-38959.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-38959.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,4141615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-3446547.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,695068.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,695068.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-12787347.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18415614.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18415614.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,244210.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1702996.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2964567.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13503841.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13503841.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-556987.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-556987.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-556987.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-4141615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,4748612.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,606997.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,606997.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-13453831.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15119181.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15119181.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,237793.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2147940.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-6624167.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-19357615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-19357615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,15844.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,15844.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,15844.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,83124548.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,83124548.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,83124548.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,63782777.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14021119.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14021119.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,272202.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2285052.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-2291303.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13755168.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13755168.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-705649.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,-15844.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-721493.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-721493.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,257256.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-347282.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-90026.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-90026.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-14566687.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20005846.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20005846.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,286168.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1922770.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,3498785.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-14298123.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-14298123.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-167516.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-167516.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-167516.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-308369.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,347282.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,38913.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,38913.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-14426726.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4405854.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4405854.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,282837.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,9000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2050238.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-14804315.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-16868094.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-16868094.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-539835.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-539835.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-539835.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,29661000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-1596435.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1680000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,29744565.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,29744565.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,12336636.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,19000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19288000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19288000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,295000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,652000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2297000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,5294000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-10750000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-10750000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-534000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-48947000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-49481000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-49481000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,57000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-309000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-252000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-252000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-60483000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22912000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22912000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,297000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,598000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2439000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,8623000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-10955000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-10955000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-80000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-80000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-80000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,10000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-65000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-55000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-55000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-11090000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,301000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,603000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2304000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,3670000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12414000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12414000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-325000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-325000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-325000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,1929000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,374000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,2303000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,2303000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-10436000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21987000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21987000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,334000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-581000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2398000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,4616000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-15220000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-15220000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1358000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,3375000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,2017000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,2017000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,19985000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,3083000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,23068000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,23068000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,9865000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,3099000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26548000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26548000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-289000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3295000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,5515000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-17630000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-17630000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-411000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-65005000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,22225000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-43191000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-43191000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,110034000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,110034000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,110034000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,49213000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16273000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16273000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,443000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,2154000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3594000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-5684000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-15766000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-15766000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-350000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-24111000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,18591000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-5870000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-5870000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,1201000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,1201000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,1201000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-20435000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20280000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20280000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,464000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,807000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,4176000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,1650000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13183000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13183000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-371000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-1000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,3000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,2628000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,2628000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,795000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,795000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,795000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-9760000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5274000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5274000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,458000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,810000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,4426000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-1359000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-939000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-939000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-236000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,233000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,13485000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,13482000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,13482000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,2471000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,2471000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,2471000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,15014000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,3460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15108000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15108000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,421000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,497000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,4130000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-3779000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13839000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13839000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-130000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-33185000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,22895000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-10420000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-10420000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,7157000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,7157000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,7157000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-17102000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,3019000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3019000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,395000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,579000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,5905000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-960000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,8938000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,8938000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-260000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,1000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,11030000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,10771000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,10771000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,3773000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,3773000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,3773000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,23482000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,402000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,508000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,5553000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,1012000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-16985000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-16985000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-336000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-13176000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,33805000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,20293000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,20293000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,437000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,437000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,437000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,3745000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,4318000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4318000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,459000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-341000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,6302000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-25935000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-15197000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-15197000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1634000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-25122000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,12000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-14756000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-14756000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,1731000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,1731000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,1731000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-28222000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q4,2015-10-01,2015-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,3775000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19816000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19816000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,489000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,1267000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,7637000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-2600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13023000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13023000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1099000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-126431000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,21908000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-105622000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-105622000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-3885000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,148046000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,285000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,144446000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,144446000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,25801000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26875000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26875000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,623000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,973000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,9862000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2572000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12845000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12845000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1167000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-11968000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,12700000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-435000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-435000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-50365000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,54959000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,826000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,5420000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,5420000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-7860000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-28946000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-28946000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,654000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,709000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,10236000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,8599000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-8748000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-8748000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-424000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-14005000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,22675000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,8246000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,8246000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-35000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,511000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,476000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,476000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-26000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27386000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27386000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,634000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,13131000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,-1960000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-196000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-15767000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-15767000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-447000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-3008000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,24500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,21045000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,21045000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,35000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,1000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,243000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,279000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,279000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,5557000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,3886000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,1441000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32897000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32897000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,602000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,1469000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,7201000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,1166000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-22459000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-22459000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-99000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-54830000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,59194000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,4265000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,4265000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2989000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-393000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-3382000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-3382000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-21576000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30763000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30763000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,570000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,509000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8236000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,4452000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-16996000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-16996000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-230000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-107062000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,58000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-49292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-49292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-3404000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,393000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,138856000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,135845000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,135845000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,69557000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,2749000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2749000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,496000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,306000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,7706000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,9002000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,20259000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,20259000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-161000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-36856000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,67300000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,30283000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,30283000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-4595000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,3705000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-890000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-890000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,49652000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,123882000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,123882000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,493000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-826000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,7401000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,22299000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,153249000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,153249000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-860000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-199439000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,51311000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-148988000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-148988000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-5007000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,5089000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,82000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,82000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,4343000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,20295000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,3015000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27461000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27461000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,566000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-130000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8471000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-3623000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-22177000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-22177000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-839000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-114661000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,79600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-35900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-35900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-17628000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,4977000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-12651000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-12651000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-70728000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22893000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22893000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,634000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-301000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,9504000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-5788000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-18844000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-18858000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-418000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-95254000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,88065000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-7607000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-7607000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-19515000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,3141000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-16374000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-16374000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-42839000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,598000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-524000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8787000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,48000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-18941000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-18927000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-333000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-62728000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,98252000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,35191000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,35191000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-19956000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,3538000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-16418000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-16418000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-154000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2126000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2126000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,590000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-590000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8932000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,3656000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,10462000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,10462000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-3073000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-38469000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,52351000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,10809000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,10809000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-20417000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,2063000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-18354000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-18354000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,2917000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,16891000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,220000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,1796000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1796000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,990000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-630000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8883000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-15463000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-4424000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-4424000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-927000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-167670000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,197410000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,28813000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,28813000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-21281000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-449000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-21730000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-21730000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,2659000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14624000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14624000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,1010000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-549000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,10222000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-20869000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-24810000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-24786000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1368000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-66014000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,114839000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,47457000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,47457000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-20692000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,449000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,4018000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-16225000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-16225000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,6446000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25015000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25015000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,1026000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-263000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8138000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-13450000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-29564000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-29588000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1104000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-7898000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,50001000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,40999000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,40999000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-21325000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,2075000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-19250000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-19250000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-7839000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,1042000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,1457000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,10033000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-4760000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-26625000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-26625000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-641000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-148177000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,26000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-122818000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-122818000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-45063000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-199998000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,447350000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,8131000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,210420000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,210420000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,60977000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,9029000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,188000.0
